microRNA Replacement Therapy
Press Releases

 
Press Releases
Date Title and Summary View
08-25-17 AUSTIN, Texas--(BUSINESS WIRE)-- Mirna Therapeutics, Inc. (Mirna) (NASDAQ: MIRN) announced today that, based upon the final vote count certified by the independent inspector of elections for the annual meeting of stockholders held August 24, 2017, its stockholders approved all of the merger-related proposals, ...
05-16-17 - Transaction Expected to Advance Synlogic's Innovative Platform for the Discovery and Development of Novel Synthetic Biotic™ Medicines - - Synlogic Closes $42 Million of Series C Preferred Stock Financing by Leading Biotechnology Investors - - Combined Company Well-Capitaliz...
05-09-17 AUSTIN, Texas--(BUSINESS WIRE)-- Mirna Therapeutics, Inc. (Nasdaq:MIRN), a biopharmaceutical company, today reported financial results for the first quarter of 2017 and provided a corporate update. Following its late 2016 discontinuation of all research and development activities, the Com...
03-14-17 AUSTIN, Texas--(BUSINESS WIRE)-- Mirna Therapeutics, Inc. (Nasdaq: MIRN), a biopharmaceutical company, today reported financial results for the fourth quarter and year ended December 31, 2016 and provided a corporate update. Following its November 2016 decision to discontinue all research and ...
11-10-16 AUSTIN, Texas--(BUSINESS WIRE)-- Mirna Therapeutics, Inc. (Nasdaq: MIRN), a biopharmaceutical company focused on microRNA-based oncology therapeutics, today reported financial results for the third quarter of 2016 and provided an update on recent developments. MRX34 CLINICAL PROGRAM ...
09-20-16 Management to host conference call and webcast today at 5 p.m. Eastern AUSTIN, Texas--(BUSINESS WIRE)-- Mirna Therapeutics, Inc. (Nasdaq:MIRN), a clinical stage biopharmaceutical company, today announced its decision to close the ongoing Phase 1 study of MRX34, its investigational microRNA t...
08-31-16 AUSTIN, Texas--(BUSINESS WIRE)-- Mirna Therapeutics, Inc. (Nasdaq:MIRN), a clinical stage biopharmaceutical company developing a pipeline of microRNA-based oncology therapeutics, today announced that senior management will participate in two upcoming healthcare investor conferences in September. ...
08-15-16 AUSTIN, Texas--(BUSINESS WIRE)-- Mirna Therapeutics, Inc. (Nasdaq:MIRN), a clinical stage biopharmaceutical company developing a pipeline of microRNA-based oncology therapeutics, today reported financial results for the second quarter of 2016 and provided an update on recent developments. ...
07-05-16 AUSTIN, Texas--(BUSINESS WIRE)-- Mirna Therapeutics, Inc. (Nasdaq:MIRN), a clinical stage biopharmaceutical company developing a broad pipeline of microRNA-based oncology therapeutics, today announced that President and Chief Executive Officer Paul Lammers, M.D., M.Sc., will present a corporate overview ...
06-30-16 AUSTIN, Texas--(BUSINESS WIRE)-- Mirna Therapeutics, Inc. (Nasdaq:MIRN), a clinical stage biopharmaceutical company developing a broad pipeline of microRNA-based oncology therapeutics, today announced the appointment of Perry Nisen, M.D., Ph.D., to the Company's Board of Directors. Dr. Nisen currently se...
Page:
1
... NextLast
= add release to Briefcase
© 2017 Mirna Therapeutics, Inc. All Rights Reserved.